Skip to main content

SYSTEMATIC REVIEW article

Front. Vet. Sci.
Sec. Veterinary Epidemiology and Economics
Volume 11 - 2024 | doi: 10.3389/fvets.2024.1397145

Use of recombinant proteins for the diagnosis and prevention of Mycoplasma bovis: A systematic review

Provisionally accepted
Camila P. Gomes Camila P. Gomes 1Lucas S. Da Silva Lucas S. Da Silva 1Manoel N. Junior Manoel N. Junior 2Maysa Santos Barbosa Maysa Santos Barbosa 3Wanderson S. Neves Wanderson S. Neves 2Viviane G. Ribeiro Viviane G. Ribeiro 2Bruno L. Bastos Bruno L. Bastos 2Lucas M. Marques Lucas M. Marques 4*
  • 1 Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brazil
  • 2 Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista, Bahia, Brazil
  • 3 University of São Paulo, São Paulo, Rio Grande do Sul, Brazil
  • 4 Federal University of Bahia (UFBA), Salvador, Brazil

The final, formatted version of the article will be published soon.

    Mycoplasma bovis is a highly contagious agent that causes various pathologies affecting herd animals' reproduction, production, and milk productivity-this systematic review aimed to analyze diagnostic alternatives and vaccine compounds based on recombinant proteins. SciELO, PubMed, and CAPES Periodicals Portal databases were searched using the PRISMA protocol. The inclusion criteria were:(1) the use of recombinant proteins for M. bovis identification or vaccine production, (2) the use of biological samples, (3) availability in the selected databases, (4) in vitro or in vivo nature of associated studies, (5) publication between 2008 and 2023, and (6) availability in English. Among the 53 studies selected, ten were relevant for the review, with four related to diagnosis and six related to vaccines. Regarding diagnosis, an indirect enzyme-linked immunosorbent assay (ELISA) using recombinant proteins was utilized in the studies, which achieved a sensitivity and specificity of > 90% for detecting M. bovis infection. However, developing recombinant vaccines for controlling M. bovis infections has not been successful. Further studies are required to determine the optimal adjuvant and challenge conditions for the protective effects of these antigens.

    Keywords: Systematic review, Mycoplasma bovis, diagnosis, Vaccine, Recombinant Proteins

    Received: 07 Mar 2024; Accepted: 28 Aug 2024.

    Copyright: © 2024 Gomes, Da Silva, Junior, Santos Barbosa, Neves, Ribeiro, Bastos and Marques. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Lucas M. Marques, Federal University of Bahia (UFBA), Salvador, Brazil

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.